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Introduction
CINCA is thought to be mainly due to a dysregulation of
IL1 synthesis and many patients respond to IL1 inhibition.
The role of other cytokines in CINCA disease pathogen-
esis is less clear.
Case Report
A 13 year old boy from a healthy non-consanguineous
family suffers from severe autoinflammatory symptoms
(persistent fever, polyserositis, urticaria, arthritis, develop-
mental delay, deafness and hepatosplenomegaly) since his
first year of life. Based on clinical presentation and geno-
type (heterozygous mutation (CAG)>Lysin (AAG)-p.
Gln703Lys/Q705K substitution in Exon 3 of NLPR3) he
was diagnosed for CINCA, an IL-1 driven cryopyrinopa-
thy. Despite intensive pretreatment (NSAI, GC pulses,
MTX, Anakinra and Canakinumab), no durable control of
autoinflammation was achievable. With the initiation of
Tozilizumab, an IL-6 receptor antagonist, all signs of auto-
inflammation disappeared, ESR and Serum Amyloid nor-
malized within days. Finally the boy was even able to build
a snowman without any joint stiffness or arthralgias for
the first time of his life. The patient is now in stable clini-
cal remission for > 6 months.
Discussion
This is the first report of a patient with CINCA, who
achieved clinical remission with the inhibition of IL6
pathway for more than 6 months. If Canakinumab fails
to control autoinflammation in CINCA inhibition of IL-6
pathway might be an alternative. The mechanism of
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